Clearside Biomedical, Inc. (NASDAQ:CLSD – Get Free Report) has received an average rating of “Buy” from the five research firms that are currently covering the firm, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $4.60.
A number of equities research analysts have recently commented on CLSD shares. Needham & Company LLC reaffirmed a “buy” rating and set a $4.00 price objective on shares of Clearside Biomedical in a research note on Monday, May 13th. JMP Securities reaffirmed a “market outperform” rating and issued a $5.00 price objective on shares of Clearside Biomedical in a report on Wednesday, March 13th. HC Wainwright decreased their price objective on shares of Clearside Biomedical from $6.00 to $5.00 and set a “buy” rating for the company in a research report on Monday, May 13th. Wedbush restated an “outperform” rating and set a $4.00 target price (down from $5.00) on shares of Clearside Biomedical in a research report on Wednesday, March 13th. Finally, StockNews.com cut Clearside Biomedical from a “hold” rating to a “sell” rating in a report on Friday, May 10th.
Read Our Latest Stock Report on CLSD
Institutional Inflows and Outflows
Clearside Biomedical Price Performance
NASDAQ CLSD opened at $1.24 on Tuesday. The company has a fifty day moving average of $1.27 and a 200 day moving average of $1.34. The company has a market capitalization of $92.67 million, a PE ratio of -2.25 and a beta of 2.43. Clearside Biomedical has a 1 year low of $0.65 and a 1 year high of $2.12.
Clearside Biomedical (NASDAQ:CLSD – Get Free Report) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.03). The firm had revenue of $0.23 million during the quarter, compared to analyst estimates of $0.98 million. During the same period in the previous year, the business posted ($0.15) earnings per share. Research analysts expect that Clearside Biomedical will post -0.63 earnings per share for the current year.
Clearside Biomedical Company Profile
Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.
Read More
- Five stocks we like better than Clearside Biomedical
- Are Penny Stocks a Good Fit for Your Portfolio?
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- 3 Warren Buffett Stocks to Buy Now
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- How to Buy Cheap Stocks Step by Step
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.